Table 1 Baseline characteristics of the AS study population
All patients | Patients with available CASSS | |
|---|---|---|
n = 98 | n = 89 | |
Male gender | 74 (76) | 66 (74) |
Age (years) | 41.8 ± 11.2 | 41.0 ± 11.1 |
Symptom duration (years) | 16 (7–24) | 16 (7–24) |
Time since diagnosis (years) | 7 (2–15) | 7 (2–16) |
HLA-B27+ | 82 (84) | 74 (83) |
BMI (kg/m2) | 26.1 ± 3.5 | 25.4 ± 3.0 |
Current smoker | 30 (37) | 28 (38) |
Total smoking duration (years) | 12 (0–25) | 12 (0–24) |
History of IBD | 9 (9) | 9 (10) |
History of uveitis | 27 (28) | 25 (28) |
History of psoriasis | 11 (11) | 11 (12) |
Peripheral arthritis | 21 (21) | 18 (20) |
NSAID use | 79 (85) | 72 (85) |
DMARD use | 23 (23) | 23 (26) |
BASDAI (0–10) | 5.9 ± 1.6 | 5.8 ± 1.7 |
ASDASCRP | 3.8 ± 0.8 | 3.8 ± 0.8 |
CRP (mg/L) | 15 (7–25) | 15 (7–25) |
Occiput-to-wall distance (cm) | 5.0 (0.0–11.1) | 4.5 (0.0–10.0) |
Lateral spinal flexion (cm) | 7.9 (5.0–11.5) | 8.1 (5.5–11.7) |
Modified Schober test (cm) | 3.0 (1.2–4.0) | 4.5 (0.0–10.0) |
Chest expansion (cm) | 3.0 (2.0–4.0) | 3.0 (2.0–4.0) |
BASFI (0–10) | 5.6 (3.7–7.1) | 5.5 (3.6–7.1) |
ASQoL (0–18) | 10 (7–13) | 9 (7–12) |